Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- WHO classification of tumours of haematopoietic and lymphoid tissues.4th edition. IARC, Lyon (France)2008
- Flow cytometry in evaluation of hematopoietic neoplasms: a case based approach.CAP Press, Northfield (IL)2012
- Multicolor immunophenotyping: human immune system hematopoiesis.Methods Cell Biol. 2004; 75: 559-576
- Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.Clin Lab Med. 2007; 27 (vii): 551-575
- Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders.Am J Clin Pathol. 2003; 120: 854-865
- Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis.Am J Clin Pathol. 1993; 100: 534-540
- CD45 gating for routine flow cytometric analysis of human bone marrow specimens.Ann N Y Acad Sci. 1993; 677: 265-280
- 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia.Cytometry B Clin Cytom. 2007; 72: S14-S22
- Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations.Am J Clin Pathol. 2005; 124: 930-936
- Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.Arch Pathol Lab Med. 2003; 127: 42-48
- The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities.Am J Clin Pathol. 1998; 109: 211-220
- A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.Cytometry B Clin Cytom. 2008; 74: 25-29
- Flow cytometric analysis of human bone marrow: I. Normal erythroid development.Blood. 1987; 69: 255-263
- Cell surface phenotyping of megakaryoblasts.Blood. 1987; 69: 957-960
- Leukemias with megakaryoblastic involvement: clinical, hematologic, and immunologic characteristics.Blood. 1988; 72: 402-407
- Intracellular expression of CD61 precedes surface expression.Ann Hematol. 1999; 78: 472-474
- False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts.Blood. 1992; 79: 2399-2403
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.Blood. 2016; 127: 2391-2405
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Blood. 2016; 127: 2375-2390
- Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia.Am J Clin Pathol. 2007; 128: 550-557
- Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21).Mod Pathol. 2004; 17: 1211-1216
- Acute myelogenous leukemia with t(8;21)–identification of a specific immunophenotype.Leuk Lymphoma. 2003; 44: 1713-1718
- Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21).Blood. 1996; 87: 1162-1169
- Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34.Blood. 1992; 80: 470-477
- Aberrant co-expression of CD19 and CD56 as surrogate markers of acute myeloid leukemias with t(8;21) in Taiwan.Int J Lab Hematol. 2008; 30: 133-138
- Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation.Am J Hematol. 2007; 82: 1-5
- Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22).Blood. 1997; 90: 1643-1648
- Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.J Clin Oncol. 2006; 24: 3904-3911
- KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.Blood. 2006; 107: 1806-1809
- Flow cytometry analysis of acute promyelocytic leukemia: the power of 'surface hematology'.Leukemia. 2007; 21: 4-8
- The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements.Haematologica. 1999; 84: 405-412
- The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes.Haematologica. 2006; 91: 311-316
- CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint.Leukemia. 1995; 9: 1461-1466
- CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.J Clin Oncol. 2000; 18: 1295-1300
- Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia.Leuk Lymphoma. 2004; 45: 1783-1789
- CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?.J Clin Oncol. 1999; 17: 293-297
- Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.Br J Haematol. 2009; 144: 798-799
- HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia.Cytometry B Clin Cytom. 2009; 76: 321-327
- HLA-DR antigen-negative acute myeloid leukemia.Leukemia. 2003; 17: 707-715
- Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.Blood. 1993; 82: 3241-3249
- All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.Blood. 1995; 85: 1202-1206
- All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.Blood. 2002; 100: 4298-4302
- Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.Hematol Oncol. 2012; 30: 109-114
- Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry.Leukemia. 1998; 12: 317-325
- Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.Leukemia. 2003; 17: 76-82
- Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.Blood. 1995; 86: 3097-3108
- Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome.Leuk Res. 2004; 28: 1007-1011
- Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?.Blood. 2007; 109: 431-448
- Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.N Engl J Med. 2005; 352: 254-266
- Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.Blood. 2007; 109: 874-885
- AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.Blood. 2009; 114: 3024-3032
- A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication.Leukemia. 2004; 18: 1591-1598
- The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination.Am J Clin Pathol. 2002; 117: 380-389
- Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias!.Haematologica. 2009; 94: 891-893
- Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system.Leukemia. 2006; 20: 620-626
- Mixed-phenotype acute leukemia: historical overview and a new definition.Leukemia. 2010; 24: 1844-1851
- Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population.Haematologica. 2009; 94: 919-927
- Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia.Br J Haematol. 2009; 145: 624-636
- Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity?.Br J Haematol. 2007; 136: 539-548
- CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells.Am J Clin Pathol. 2007; 127: 687-700
- The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.Leukemia. 2006; 20: 1783-1789
- Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.J Clin Oncol. 2013; 31: 4123-4131
- Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.Blood. 2013; 121: 2213-2223
- Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.Blood. 2004; 104: 3078-3085
- Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.J Clin Oncol. 2011; 29: 2709-2716
- Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.Blood. 2001; 98: 1746-1751
- High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.J Clin Oncol. 2013; 31: 3889-3897
- Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.Blood. 2000; 96: 3948-3952
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.Blood. 2012; 120: 2826-2835
- The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.Am J Clin Pathol. 2009; 131: 16-26
- Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.Cytometry B Clin Cytom. 2016; 90: 47-53
- Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting.Blood Cancer J. 2013; 3: e129
- Characterization of aberrant phenotypes in acute myeloblastic leukemia.Ann Hematol. 1995; 70: 189-194
- Expression of unusual immunophenotype combinations in acute myelogenous leukemia.Blood. 1993; 81: 3083-3090
- Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.Am J Clin Pathol. 2008; 129: 934-945
- Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.Cytometry B Clin Cytom. 2005; 68: 18-24
- Tumor heterogeneity makes AML a “moving target” for detection of residual disease.Cytometry B Clin Cytom. 2014; 86: 3-14
- High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).Blood. 2001; 97: 3574-3580
- Immunophenotypic differences between diagnosis and relapse in childhood AML: implications for MRD monitoring.Cytometry B Clin Cytom. 2005; 63: 1-9
- Flow cytometric monitoring of residual disease in acute leukemia.Methods Mol Biol. 2013; 999: 123-136
Article info
Publication history
Published online: August 30, 2017
Footnotes
Disclosure: The authors have no commercial or financial conflicts of interest or any funding sources relevant to this article.
Identification
Copyright
© 2017 Elsevier Inc. All rights reserved.
